Vitamin D3 intake as regulator of insulin degrading enzyme and insulin receptor phosphorylation in diabetic rats

Biomedicine and Pharmacotherapy

Volumn 85, Issue , 2017, Pages 155-159

  Elseweidy, Mohamed Mahmoud ^a   Amin, Rawia Sarhan ^a   Atteia, Hebatallah Husseini ^a   Ali, Maha Abdo ^a  

^a Zagazig University   (Egypt)

Author keywords

Glucagon; Hyperlipidemia; Insulin degrading enzyme; Insulin receptors phosphorylation; Insulin resistance

Indexed keywords

COLECALCIFEROL; GLUCAGON; GLUCOSE; INSULIN RECEPTOR; INSULINASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DYSLIPIDEMIA; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; INSULIN RESISTANCE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; TRIACYLGLYCEROL BLOOD LEVEL; VITAMIN INTAKE; ANIMAL; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHOSPHORYLATION; RANDOMIZATION; WISTAR RAT;

ANIMALS; CHOLECALCIFEROL; DIABETES MELLITUS, EXPERIMENTAL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; INSULYSIN; MALE; PHOSPHORYLATION; RANDOM ALLOCATION; RATS; RATS, WISTAR; RECEPTOR, INSULIN;

EID: 85000799303     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2016.11.116     Document Type: Article

References (56)

1. [1] Bray, G.A., Nielsen, S.J., Popkin, B.M., Consumption of high-fructose corn syrup in beverages may play a role in the epidemic of obesity. Am. J. Clin. Nutr. 79:4 (2004), 537–543.
2. [2] Rutledge, A.C., Adeli, K., Fructose and the metabolic syndrome: pathophysiology and molecular mechanisms. Nutr. Rev. 65:1 (2007), S13–S23.
3. [3] Mamikutty, Norshalizah, Thent, Zar Chi, Sapri, Shaiful Ridzwan, Sahruddin, Natasya Nadia, Mohd Yusof, Mohd Rafizul, Suhaimi, Farihah Haji, The establishment of metabolic syndrome model by inductionof fructose drinking water in male wistar rats. BioMed Res. Int., 2014, 2014 Article ID 263897, 8 pages.
4. [4] Boucher, B.J., Mannan, N., Noonan, K., Hales, C.N., Evans, S.J., Glucose intolerance and impairment of insulin secretion in relation to vitamin D deficiency in east London Asians. Diabetologia 38 (1995), 1239–1245.
5. [5] Orwoll, E., Riddle, M., Prince, M., Effects of vitamin D on insulin and glucagon secretion in non-insulin-dependent diabetes mellitus. Am. J. Clin. Nutr. 59 (1994), 1083–1087.
6. [6] Kumar, S., Davies, M., Zakaria, Y., Mawer, E.B., Gordon, C., Olukoga, A.O., et al. Improvement in glucose tolerance and beta-cell function in a patient with vitamin D deficiency during treatment with vitamin D. Postgrad. Med. J. 70 (1994), 440–443.
7. [7] Mark, R.H., 1,25-Dihydroxyvitamin D3 corrects insulin and lipid abnormalities in uremia. Kidney Int. 53 (1998), 1353–1357.
8. [8] Nagpal, J., Pande, J.N., Bhartia, A., A double-blind, randamoized, placebo-controlled trial of the short term effect of vitamin D3 supplementation on insulin sensitivity in apparently healthy, middle-aged, centrally obese men. Diabet. Med. 26 (2009), 19–27.
9. [9] Pinelli, N.R., Jaber, L.A., Brown, M.B., Herman, W.H., Serum 25-hydroxy vitamin D and insulin resistance, metabolic syndrome, and glucose intolerance among Arab Americans. Diabetes Care 33 (2010), 1373–1375.
10. [10] Scragg, R., Holdaway, I., Singh, V., Metcalf, P., Baker, J., Dryson, E., Serum 25-hydroxyvitamin D3 levels decreased in impaired glucose tolerance and diabetes mellitus. Diabetes Res. Clin. Pract. 27:March (3) (1995), 181–188.
11. [11] Pittas, A.G., Lau, J., Hu, F.B., Dawson-Hughes, B., The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 92:6 (2007), 2017–2029.
12. [12] Johnson, J.A., Grande, J.P., Roche, P.C., Kumar, R., Immunohistochemical localization of the 1 25(OH)2D3 receptor and calbindin D28k in human and rat pancreas. Am. J. Physiol. 267:3, part 1 (1994), E356–E360.
13. [13] Rosen, C.J., Adams, J.S., Bikle, D.D., Black, D.M., Demay, M.B., Manson, J.E., et al. The nonskeletal effects of vitamin D: an endocrine society scientific statement. Endocr. Rev. 33 (2012), 456–492.
14. [14] Maestro, B., Davila, N., Carranza, M.C., Calle, C., Identification of a vitamin D response element in the human insulin receptor gene promoter. J. Steroid Biochem. Mol. Biol. 84:2–3 (2003), 223–230.
15. [15] Maestro, B., Molero, S., Bajo, S., D́avila, N., Calle, C., Transcriptional activation of the human insulin receptor gene by 1,25-dihydroxyvitamin D3. Cell Biochem. Funct. 20:3 (2002), 227–232.
16. [16] Dunlop, T.W., V̈ais̈anen, S., Frank, C., Molńar, F., Sinkkonen, L., Carlberg, C., Karn, J., The human peroxisome proliferator-activated receptor δ gene is a primary target of 1α,25-dihydroxyvitamin D3 and its nuclear receptor. J. Mol. Biol. 349:2 (2005), 248–260.
17. [17] Maestro, B., Campion, J., Davila, N., Calle, C., Stimulation by 1,25-dihydroxyvitamin D3 of insulin receptor expression and insulin responsiveness for glucose transport in U-937 human promonocytic cells. Endocr. J. 47:4 (2000), 383–391.
18. [18] White, M.F., Shoelson, S.E., Keutmann, H., Kahn, C.R., A cascade of tyrosine autophosphorylation in the beta-subunit activates the phosphotransferase of the insulin receptor. J. Biol. Chem. 263:February (6) (1988), 2969–2980.
19. [19] Cheatham, B., Vlahos, C.J., Cheatham, L., Wang, L., Blenis, J., Kahn, C.R., Phosphatidylinositol 3-kinase activation is required for insulin stimulation of pp70 S6 kinase, DNA synthesis, and glucose transporter translocation. Mol. Cell. Biol. 14:July (7) (1994), 4902–4911.
20. [20] Fu, M., Sun, T., Bookout, A.L., Downes, M., Yu, R.T., Evans, R.M., et al. A nuclear receptor atlas: 3T3-L1 adipogenesis. Mol. Endocrinol. 19 (2005), 2437–2450.
21. [21] Narvaez, C.J., Simmons, K.M., Brunton, J., Salinero, A., Chittur, S.V., Welsh, J.E., Induction of STEAP4 correlates with 1,25-dihydroxyvitamin D3 stimulation of adipogenesis in mesenchymal progenitor cells derived from human adipose tissue. J. Cell. Physiol. 228 (2013), 2024–2036.
22. [22] Wood, R.J., Vitamin D, and adipogenesis: new molecular insights. Nutr. Rev. 66 (2008), 40–46.
23. [23] Ryan, K.J., Daniel, Z.C., Craggs, L.J., Parr, T., Brameld, J.M., Dose-dependent effects of vitamin D on transdifferentiation of skeletal muscle cells to adipose cells. J. Endocrinol. 217 (2013), 45–58.
24. [24] Forouhi, N.G., Ye, Z., Rickard, A.P., Khaw, K.T., Luben, R., Langenberg, C., et al. Circulating 25-hydroxyvitamin D concentration and the risk of type 2 diabetes: results from the European Prospective Investigation into Cancer (EPIC)–Norfolk cohort and updated meta-analysis of prospective studies. Diabetologia 55 (2012), 2173–2182.
25. [25] Scragg, R., Sowers, M., Bell, C., Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the third national health and nutrition examination survey. Diabetes Care 27 (2004), 2813–2818.
26. [26] George, P.S., Pearson, E.R., Witham, M.D., Effect of vitamin D supplementation on glycaemic control and insulin resistance: a systematic review and meta-analysis. Diabet. Med. 29 (2012), e142–e150.
27. [27] Shen, Y., Joachimiak, A., Rosner, M.R., Tang, W.J., Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism. Nature 443 (2006), 870–874.
28. [28] Grasso, G., Pietropaolo, A., Spoto, G., Pappalardo, G., Tundo, G.R., et al. Copper(I) and copper(II) inhibit Abeta peptides proteolysis by insulin-degrading enzyme differently: implications for metallostasis alteration in Alzheimer's disease. Chemistry 17 (2011), 2752–2762.
29. [29] Cordes, C.M., Bennett, R.G., Siford, G.L., Hamel, F.G., Nitric oxide inhibits insulin-degrading enzyme activity and function through S-nitrosylation. Biochem. Pharmacol. 77 (2009), 1064–1073.
30. [30] Farris, W., Mansourian, S., Chang, Y., Lindsley, L., Eckman, E.A., et al. Insulin degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 4162–4167.
31. [31] Berger, J., Moller, D.E., The mechanisms of action of PPARs. Annu. Rev. Med. 53 (2002), 409–435.
32. [32] Kuchay, M.S., Laway, B.A., Bashir, M.I., Wani, A.I., Misgar, R.A., Shah, Z.A., Effect of vitamin D supplementation on glycemic parameters and progression of prediabetes to diabetes: a 1-year, open-label randomized study. Indian J. Endocrinol. Metab. 19:May–June (3) (2015), 387–392.
33. [33] Bevan, P., Insulin signaling. J. Cell. Sci. 114 (2001), 1429–1430.
34. [34] Junlan, Z., Gangjian, Q., Review article: adipocyte dysfunction and hypertension. Am. J. Cardiovasc. 2:2 (2012), 143–149.
35. [35] Kershaw, E.E., Flier, J.S., Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab. 89:6 (2004), 2548–2556.
36. [36] Paschos, P., Paletas, K., Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia 13:1 (2009), 9–19.
37. [37] Duckworth, W.C., Bennett, R.G., Hamel, F.G., Insulin degradation: progress and potential. Endocr. Rev. 19 (1998), 608–624.
38. [38] Hulse, R.E., Ralat, L.A., Wei-Jen, T., Structure, function, and regulation of insulin-degrading enzyme. Vitam. Horm. 80 (2009), 635–648.
39. [39] Farris, W., Mansourian, S., Chang, Y., Lindsley, L., Eckman, E.A., et al. Insulin-degradingenzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 4162–4167.
40. [40] Wei, Xiuqing, Ke, Bilun, Zhao, Zhiyun, Ye, Xin, Gao, Zhanguo, Ye, Jianping, Regulation of insulin degrading enzyme activity by obesity-associated factors and pioglitazone in liver of diet-induced obese mice. PLoS One, 9(April (4)), 2014, e95399.
41. [41] Khan, H., Kunutsor, S., Franco, O.H., Chowdhury, R., Vitamin D, type 2 diabetes andother metabolic outcomes: a systematic review and meta-analysis of prospectivestudies. Proc. Nutr. Soc. 72 (2013), 89–97.
42. [42] Rosenblum, J.L., Castro, V.M., Moore, C.E., Kaplan, L.M., Calcium and vitamin D supplementation is associated with decreased abdominal visceral adipose tissuein overweight and obese adults. Am. J. Clin. Nutr. 95 (2012), 101–108.
43. [43] Sadek, K.M., Shaheen, H., Biochemical efficacy of vitamin D in amelioratingendocrine and metabolic disorders in diabetic rats. Pharm. Biol. 52 (2014), 591–596.
44. [44] Duckworth, W.C., Bennett, R.G., Hamel, F.G., Insulin degradation: progress and potential. Endocr. Rev. 19:5 (1998 Oct), 608–624.
45. [45] Butterfield, W.J., Insulin clearance in nondiabetic and diabetic subjects. Panminerva Med. 12 (1970), 233–235.
46. [46] Mittelman, S.D., Van Citters, G.W., Kim, S.P., Davis, D.A., Dea, M.K., Hamilton-Wessler, M., Bergman, R.N., Longitudinal compensation for fat-induced insulin resistance includes reduced insulin clearance and enhanced β-cell response. Diabetes 49 (2000), 2116–2125.
47. [47] Kotronen, A., Juurinen, L., Tiikkainen, M., Vehkavaara, S., Yki-Järvinen, H., Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes. Gastroenterology 135 (2008), 122–130.
48. [48] Amata, O., Marino, T., Russo, N., Toscano, M., Human insulin-degrading enzyme working mechanism. J. Am. Chem. Soc. 131 (2009), 14804–14811.
49. [49] Li, C.Z., Zhang, S.H., Shu, C.D., Ren, W., Relationship between insulin-degrading enzyme activity and insulin sensitivity in cell model of insulin-resistance. Di Yi Jun Yi Da Xue Bao 22 (2002), 151–154.
50. [50] Leissring, M.A., Malito, E., Hedouin, S., Reinstatler, L., Sahara, T., Abdul-Hay, S.O., Choudhry, S., Maharvi, G.M., Fauq, A.H., Huzarska, M., et al. Designed inhibitors of insulin-degrading enzyme regulate the catabolism and activity of insulin. PLoS One, 5, 2010, e10504.
51. [51] Karamohamed, S., Demissie, S., Volcjak, J., Liu, C., Heard-Costa, N., Liu, J., Shoemaker, C.M., Panhuysen, C.I., Meigs, J.B., Wilson, P., et al. Polymorphisms in the insulin-degrading enzyme gene are associated with type 2 diabetes in men from the NHLBI Framingham Heart Study. Diabetes 52 (2003), 1562–1567.
52. [52] Slominskiĭ, P.A., Pivovarova, O.V., Shadrina, M.I., Artem'eva, A.V., Pfaipffer, F.G., Rudovich, N.N., Agadzhanian, S.E., Pronin, V.S., Limborskaia, S.A., Association of insulinase gene polymorphisms with type 2 diabetes mellitus in patients from the Moscow population. Genetika 45 (2009), 127–131.
53. [53] Matveyenko, A.V., Veldhuis, J.D., Butler, P.C., Adaptations in pulsatile insulin secretion, hepatic insulin clearance, and β-cell mass to age-related insulin resistance in rats. Am. J. Physiol. Endocrinol. Metab. 295 (2008), E832–E841.
54. [54] Rezende, L.F., Santos, G.J., Santos-Silva, J.C., Carneiro, E.M., Boschero, A.C., Ciliaryneurotrophic factor (CNTF) protects non-obese Swiss mice against type 2 diabetes by increasing β cell mass and reducing insulin clearance. Diabetologia 55 (2012), 1495–1504.
55. [55] Hamel, F.G., Upward, J.L., Bennett, R.G., In vitro inhibition of insulin-degrading enzyme by long-chain fatty acids and their coenzyme A thioesters. Endocrinology 144 (2003), 2404–2408.
56. [56] Yoshii, H., Lam, T.K., Gupta, N., Goh, T., Haber, C.A., Uchino, H., Kim, T.T., Chong, V.Z., Shah, K., Fantus, I.G., et al. Effects of portal free fatty acid elevation on insulin clearance and hepatic glucose flux. Am. J. Physiol. Endocrinol. Metab. 290 (2006), E1089–E1097.